BioMarin Pharma (NASDAQ: BMRN) reported Q1 EPS of $0.71, $0.39 better than the analyst estimate of $0.32. Revenue for the quarter came in at $649 million versus the consensus estimate of $649.27 million.

GUIDANCE:

BioMarin Pharma sees FY2024 EPS of $2.75-$2.95, versus the consensus of $2.75. BioMarin Pharma sees FY2024 revenue of $2.7-2.8 billion, versus the consensus of $2.76 billion.

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.